BY OUR PLATFORMS
BY THERAPEUTIC AREA
BY RESEARCH STAGE
26 November 2018
Many of you are aware of our CRISPR/cas9 license from MIT Harvard, which together with our in-house expertise has allowed us to develop ZeGenesis, an extensive collection of zebrafish transgenic models spanning across multiple therapeutic areas.
The continuous growth of our ZeGenesis activities calls for new resources and in line with ZeClinics' commitment to recruit young talent, we are proud to announce the addition of Dr. Flavia De Santis to our dynamic team.
Flavia is an expert in the field of gene editing. She got her PhD from the Universitè Pierre et Marie Curie (Paris). She have a strong experience in zebrafish neurobiology and molecular biology; she master different genome editing techniques and she is an expert of CRISPR/Cas9 applications in zebrafish. She was awarded with a Torres y Quevedo grant in order to join ZeClinics.
We are confident that Flavia's arrival will contribute immediately to our ZeGenesis portfolio and ensure success for our customers and partners.
Welcome aboard Flavia!
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.